Literature DB >> 1851241

Regulation of CD45 expression in human leukemia cells.

R Taetle1, H Ostergaard, M Smedsrud, I Trowbridge.   

Abstract

The CD45 antigen cluster identifies a family of transmembrane glycoprotein tyrosine phosphatases (PTPases) present on nearly all hemopoietic cells. Recent studies suggest that CD45 may play a role in the control of receptor mediated blood cell responses, and that expression of the CD45 gene varies during bone marrow cell maturation. However, relatively little is known of the mechanisms controlling CD45 expression and function. Here we show that the induction of granulocyte or monocyte differentiation of HL60 leukemia cells is accompanied by a rapid increase in CD45 antigen expression and CD45 PTPase activity. In contrast, other leukemia cell lines induced for monocyte/macrophage differentiation did not show increased CD45. Immunoprecipitation of radiolabelled CD45 glycoprotein from dimethyl sulphoxide (DMSO) treated HL60 cells indicated that the cells expressed 200 and 180 kD isoforms. Northern blots of steady-state RNA from HL60 cells showed a 4-11-fold increase in CD45 transcripts after DMSO treatment, but no alteration in the half-life of CD45 mRNA. Nuclear transcription assays showed that CD45 expression was controlled at the level of gene transcription. Namalwa Burkitt leukemia cells expressing the heterologous epidermal growth factor (EGF) receptor protein tyrosine kinase were used to assess the specificity of CD45 PTPase activity. Co-clustering of CD45 and the EGF receptor with specific monoclonal antibodies failed to alter the EGF stimulated tyrosine phosphorylation of the EGF receptor. These studies indicate that CD45 increases during myeloid maturation, and the expression of the CD45 gene is controlled at the level of gene transcription. Preliminary studies suggest that CD45 does not alter the protein tyrosine kinase activity of the EGF receptor in intact cells, suggesting substrate specificity in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851241

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

1.  Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.

Authors:  John M Pagel; Dana C Matthews; Aimee Kenoyer; Donald K Hamlin; Daniel S Wilbur; Darrell R Fisher; Ajay K Gopal; Yukang Lin; Laura Saganic; Frederick R Appelbaum; Oliver W Press
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

2.  Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.

Authors:  Raya Mawad; Ted A Gooley; Joseph G Rajendran; Darrell R Fisher; Ajay K Gopal; Andrew T Shields; Brenda M Sandmaier; Mohamed L Sorror; Hans Joachim Deeg; Rainer Storb; Damian J Green; David G Maloney; Frederick R Appelbaum; Oliver W Press; John M Pagel
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-20       Impact factor: 5.742

3.  Pretargeted radioimmunotherapy for hematologic and other malignancies.

Authors:  Roland B Walter; Oliver W Press; John M Pagel
Journal:  Cancer Biother Radiopharm       Date:  2010-04       Impact factor: 3.099

4.  Identification of polymorphonuclear leukocyte and HL-60 cell receptors for adhesins of Streptococcus gordonii and Actinomyces naeslundii.

Authors:  S Ruhl; J O Cisar; A L Sandberg
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

5.  Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.

Authors:  John M Pagel; Theodore A Gooley; Joseph Rajendran; Darrell R Fisher; Wendy A Wilson; Brenda M Sandmaier; Dana C Matthews; H Joachim Deeg; Ajay K Gopal; Paul J Martin; Rainer F Storb; Oliver W Press; Frederick R Appelbaum
Journal:  Blood       Date:  2009-09-28       Impact factor: 22.113

6.  Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.

Authors:  John M Pagel; Nathan Hedin; Lacey Drouet; Brent L Wood; Anastasia Pantelias; Yukang Lin; Donald K Hamlin; D Scott Wilbur; Ajay K Gopal; Damian Green; Frederick R Appelbaum; Oliver W Press
Journal:  Blood       Date:  2007-11-27       Impact factor: 22.113

7.  Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.

Authors:  Johnnie J Orozco; Ethan R Balkin; Ted A Gooley; Aimee Kenoyer; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Mark D Hylarides; Mazyar Shadman; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

8.  Pituitary adenylate cyclase-activating polypeptide (PACAP) contributes to the proliferation of hematopoietic progenitor cells in murine bone marrow via PACAP-specific receptor.

Authors:  Zhifang Xu; Hirokazu Ohtaki; Jun Watanabe; Kazuyuki Miyamoto; Norimitsu Murai; Shun Sasaki; Minako Matsumoto; Hitoshi Hashimoto; Yutaka Hiraizumi; Satoshi Numazawa; Seiji Shioda
Journal:  Sci Rep       Date:  2016-02-29       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.